Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Characterizing the physiological importance of serotonin receptor-mediated inhibition on Brown Adipose Tissue (BAT) metabolic activity in regulating energy expenditure.
EF 2017-18
Résumé
Obesity is characterized by a chronic energy imbalance in which caloric intake exceeds energy expenditure (EE). In Canada, the prevalence of obesity continues to rise; approximately 60% of adults and 25% of adolescents are classified as overweight and/or obese. Obese individuals have an increased risk for several associated comorbidities, such as many cancers, type 2 diabetes, cardiovascular diseases, and non-alcoholic fatty liver disease (NAFLD). Thus, there is an increased need for new therapies aimed at safely stimulating EE. Obesity is associated with a reduced activity of brown adipose tissue (BAT). In obesity, one hormone that has been demonstrated to inhibit BAT is peripheral serotonin (5HT). In vivo and in vitro data has demonstrated that chemical inhibition of the serotonin receptor 5HTR2a blocks the effects of serotonin to inhibit BAT thermogenesis. Therefore, we hypothesize that genetic deletion of 5HTR2a in mice will protect and reverse obesity due to increases in BAT activity and energy expenditure. This experiment will be carried out in 5HTR2a floxed mice, crossed with adiponectin-CreERT2 mice, to allow for selective deletion of 5HTR2a in adipose tissue. These data will reveal a novel role for adipose tissue 5HTR2a in regulating BAT metabolic activity and EE. This approach differs from previous attempts to activate BAT, which have led to safety concerns including high blood pressure. Therefore, this novel therapeutic strategy may lead to safe and efficacious pharmacotherapies for treating obesity.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386390
Name
Morrow Marisa
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing the physiological importance of serotonin receptor-mediated inhibition on Brown Adipose Tissue (BAT) metabolic activity in regulating energy expenditure.
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Beige Adipose Tissue; Brown Adipose Tissue; Energy Expenditure; Metabolism; Obesity; Serotonin
Abstract
Obesity is characterized by a chronic energy imbalance in which caloric intake exceeds energy expenditure (EE). In Canada, the prevalence of obesity continues to rise; approximately 60% of adults and 25% of adolescents are classified as overweight and/or obese. Obese individuals have an increased risk for several associated comorbidities, such as many cancers, type 2 diabetes, cardiovascular diseases, and non-alcoholic fatty liver disease (NAFLD). Thus, there is an increased need for new therapies aimed at safely stimulating EE. Obesity is associated with a reduced activity of brown adipose tissue (BAT). In obesity, one hormone that has been demonstrated to inhibit BAT is peripheral serotonin (5HT). In vivo and in vitro data has demonstrated that chemical inhibition of the serotonin receptor 5HTR2a blocks the effects of serotonin to inhibit BAT thermogenesis. Therefore, we hypothesize that genetic deletion of 5HTR2a in mice will protect and reverse obesity due to increases in BAT activity and energy expenditure. This experiment will be carried out in 5HTR2a floxed mice, crossed with adiponectin-CreERT2 mice, to allow for selective deletion of 5HTR2a in adipose tissue. These data will reveal a novel role for adipose tissue 5HTR2a in regulating BAT metabolic activity and EE. This approach differs from previous attempts to activate BAT, which have led to safety concerns including high blood pressure. Therefore, this novel therapeutic strategy may lead to safe and efficacious pharmacotherapies for treating obesity.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Morrow, Marisa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~